» Articles » PMID: 24106867

Practices That Reduce the Latina Survival Disparity After Breast Cancer

Overview
Date 2013 Oct 11
PMID 24106867
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Latina breast cancer patients are 20 percent more likely to die within 5 years after diagnosis compared with white women, even though they have a lower incidence of breast cancer, lower general mortality rates, and some better health behaviors. Existing data only examine disparities in the utilization of breast cancer care; this research expands the study question to which utilization factors drive the shorter survival in Latina women compared with white women.

Methods: This longitudinal linked Surveillance Epidemiology and End Results (SEER)-Medicare cohort study examined early stage breast cancer patients diagnosed between 1992 and 2000 and followed for 5-11 years after diagnosis (N=44,999). Modifiable utilization factors included consistent visits to primary care providers and to specialists after diagnosis, consistent post-diagnosis mammograms, and receipt of initial care consistent with current standards of care.

Results: Of the four utilization factors potentially driving this disparity, a lack of consistent post-diagnosis mammograms was the strongest driver of the Latina breast cancer survival disparity. Consistent mammograms attenuated the hazard of death from 23% [hazard ratio, HR, (95% confidence interval, 95%CI)=1.23 (1.1,1.4)] to a nonsignificant 12% [HR (95%CI)=1.12 (0.7,1.3)] and reduced the excess hazard of death in Latina women by 55%. Effect modification identified that visits to primary care providers have a greater protective impact on the survival of Latina compared to white women [HR (95%CI)=0.9 (0.9,0.9)].

Conclusions: We provide evidence that undetected new or recurrent breast cancers due to less consistent post-diagnosis mammograms contribute substantially to the long-observed Latina survival disadvantage. Interventions involving primary care providers may be especially beneficial to this population.

Citing Articles

Early Stage Breast Cancer: Does Histologic Subtype (Ductal vs. Lobular) Impact 5 Year Overall Survival?.

Mubarak F, Kowkabany G, Popp R, Bansal S, Ahmed S, Sharan S Cancers (Basel). 2024; 16(8).

PMID: 38672591 PMC: 11049226. DOI: 10.3390/cancers16081509.


Patterns of Evidence-Based Care for the Diagnosis, Staging, and First-line Treatment of Breast Cancer by Race-Ethnicity: A SEER-Medicare Study.

Herbach E, Nash S, Lizarraga I, Carnahan R, Wang K, Ogilvie A Cancer Epidemiol Biomarkers Prev. 2023; 32(10):1312-1322.

PMID: 37436422 PMC: 10592343. DOI: 10.1158/1055-9965.EPI-23-0218.


Literature review of data-based models for identification of factors associated with racial disparities in breast cancer mortality.

Prieto D, Soto-Ferrari M, Tija R, Pena L, Burke L, Miller L Health Syst (Basingstoke). 2019; 8(2):75-98.

PMID: 31275571 PMC: 6598506. DOI: 10.1080/20476965.2018.1440925.


How Does Managed Care Improve the Quality of Breast Cancer Care Among Medicare-Insured Minority Women?.

Smith-Gagen J, Loux T, Drake C, Perez-Stable E J Racial Ethn Health Disparities. 2016; 3(3):496-507.

PMID: 27294748 DOI: 10.1007/s40615-015-0167-y.

References
1.
Ashing-Giwa K, Padilla G, Bohorquez D, Tejero J, Garcia M . Understanding the breast cancer experience of Latina women. J Psychosoc Oncol. 2006; 24(3):19-52. DOI: 10.1300/J077v24n03_02. View

2.
Weinberg C . Interaction and exposure modification: are we asking the right questions?. Am J Epidemiol. 2012; 175(7):602-5. PMC: 3324436. DOI: 10.1093/aje/kwr495. View

3.
Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy S . Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol. 2009; 20(9):1505-1510. DOI: 10.1093/annonc/mdp037. View

4.
Breen N, Gentleman J, Schiller J . Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer. 2011; 117(10):2209-18. PMC: 3117095. DOI: 10.1002/cncr.25679. View

5.
Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R . Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011; 29(13):1657-63. DOI: 10.1200/JCO.2010.32.2933. View